Completed PHASE2 INTERVENTIONAL 2-arm NCT00016367

Cisplatin and Gemcitabine Plus Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase II Multidose, Single Arm, Multicenter Clinical Trial of Cisplatin and Gemcitabine in Combination With Recombinant Humanized Anti-p185HER2 Monoclonal Antibody (Herceptin) in Patients Who Have Untreated p185HER2 Overexpressing Advanced Local Stage (Stage IIIb Pleural Effusion Only) and Metastatic (Stage IV) Non-Small Cell Lung Cancer

Sponsor: M.D. Anderson Cancer Center

Conditions Lung Cancer

Interventions Cisplatin Gemcitabine Hydrochloride Trastuzumab

Updated 6 times since 2017 Last updated: Oct 25, 2018 Started: May 13, 1999 Primary completion: Dec 14, 2004 Completion: Dec 14, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00016367, this PHASE2 trial focuses on Lung Cancer and remains completed. Sponsored by M.D. Anderson Cancer Center, it has been updated 6 times since 1999, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Nov 2018 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Nov 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

May 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States